S-GE Impulse: Life Science, April 14, 2015, Messe Basel GLOBAL BIOTECH

Transcription

1 S-GE Impulse: Life Science, April 14, 2015, Messe Basel GLOBAL BIOTECH OFFICIAL PROGRAM PREMIUM PARTNER

2 Overview Most biotech companies seek an international strategy and orientation, either for their entire business or for individual industries. The «S-GE Impulse: Life Science» event, which forms part of the Swiss Biotech Day 2015, offers practical examples to showcase the advantages cluster formation offers to Swiss SMEs in the biotech sector in different markets and their respective benefits. Thanks to field reports from Swiss biotech companies, the participants gain an understanding of the potential inherent in the export of biotech, the challenges they face, and what they need to consider to successfully gain a foothold abroad. MORE INFORMATION THE SWISS BIOTECH DAY 2015 The Swiss Biotech Day is the leading biotechnology conference in Switzerland. The upcoming event will bring together around 400 senior executives from the life science industry across Europe. Program highlights will be keynotes by Joseph Jimenez (Novartis AG) and Holger Zinke (BRAIN AG), as well as the presentation of the Swiss Biotech Report. The parallel sessions in the afternoon will focus on: Innovations in Healthcare, Regulatory Affairs, Listed Biotech Companies (Investor & Analyst Track) and Hotspots in Biotech. Additionally, there will be an exhibition and extensive networking opportunities throughout the day. Do not miss the opportunity to meet top-ranking representatives of the European life science sector. CONTACT PASCAL BLANC Head of Trade Fairs pblanc@s-ge.com T

3 Program CONTACT T F REGISTER NOW s-ge.com/impulselifescience APRIL 14, 2015 MESSE BASEL Welcome MARKUS WYSS, Head of Markets + Consultants, Liability and crisis management challenges for the Life Science Industry MARKUS KÄLIN, DR. SC.NAT. ETH, Global Head of Casualty Risk Engineering, XL Insurance Opening remarks to global biotech hotspots STEVEN DICKMAN, CBT Advisors, One Broadway, Cambridge, USA 14:10 Switzerland: a competitive ecosystem for biotech entrepreneurs JAN LICHTENBERG, Ph.D., Co-Founder and CEO of InSphero AG, Switzerland 14:30 Singapore s Biomedical Sciences Initiative: 15 Years On MR MARVIN NG, Principal Consultant, DN Venture Partners LLP, Singapore 14:50 The Cambridge eco-system: collaborative opportunities HARRIET FEAR, CEO at One Nucleus and UK Business Ambassador for the British Prime Minister 15:10 Massachutsetts: The World s Leading Ecosystem for Life Sciences Innovation and Growth MR ANGUS MCQUILKEN, Vice President for Marketing & Communications, Massachusetts Life Sciences Center BREAK Lifescience: Swiss location from research to innovation ANDRÉ SCHNEIDER, Vice-Présidence Ressources et Infrastructures (VPRI) EPFL Paneldiscussion with MR MARVIN NG, Singapore MRS HARRIET FEAR, UK MR ANGUS MCQUILKEN, USA MR ANDRÉ SCHNEIDER, Switzerland INSPHERO AG, Switzerland moderated by STEVEN DICKMAN End 3

4 Speakers DR. MARKUS KÄLIN, DR. SC.NAT. ETH Global Head of Casualty Risk Engineering, XL Insurance Markus has spent the past 20 years of his career using his risk management, natural sciences and international insurance experience to consult within the pharmaceutical, medical devices and food and beverages industry. He joined XL Group in 1993 and held various positions within Environmental Technical Services, Property and Casualty Risk Engineering, Product Management before he took over in 2012 the lead of the Global Casualty Risk Engineering team of XL Group. Markus earned a master of science in biotechnology from the Swiss Federal Institute of Technology, in Zürich and a PhD in biotechnology and genetic engineering for the same university. JAN LICHTENBERG CEO and Co-Founder InSphero AG Jan Lichtenberg, Ph.D., is Co-Founder and CEO of InSphero AG, Switzerland, the largest supplier of 3D cell-culture products for pharmaceutical customers worldwide. InSphero produces biological 3D microtissues mimicking the structure and functionality of tissue, e.g. liver, heart muscle or skin. The 3D microtissues allow for more predictive compound profiling for efficacy and toxicology screening, especially liver toxicology and oncology. Jan co-founded InSphero in 2009 and grew the company to 30+ employees in Switzerland, Germany, and the US while expanding the business to encompass all top 15 global pharmaceutical companies. Prior, Jan had R&D and Product Management positions at Hocoma AG (medical robotics) and Uwatec (microelectronics). He holds a Ph.D. from the University of Neuchâtel and managed a research group at the Swiss Federal Institute of Technology, Zurich. MARVIN NG Principal Consultant, DN Venture Partners LLP (Singapore) Marvin is principal consultant at DN Venture Partners LLP, a Singapore-based business development advisory firm that helps life science organisations expand their business activities into Asia. He is also co-editor of the Singapore Biotech Guide ( and the Singapore Medtech Portal ( Prior to setting up DN Venture Partners in 2002, Marvin worked at the Singapore Economic Development Board where he was responsible for investment promotion to European pharmaceutical and medtech companies. 4

5 HARRIET FEAR CEO at One Nucleus and UK Business Ambassador for the British Prime Minister Harriet joined One Nucleus (formerly ERBI) as CEO in February She previously worked as a Diplomat with the British Foreign Office for 21 years serving in over 17 countries around the globe. Half her career was spent in the commercial field, latterly heading UK Trade & Investments national life sciences trade team for over 5 years. During her varied Foreign Office career she was Deputy Ambassador three times, Private Secretary to the Minister for Europe, led an evacuation of Brits out of the Congo and worked in Khymer Rouge territory with Scotland Yard on a hostage crisis. In January 2014 Harriet became a UK Business Ambassador for the British Prime Minister at his invitation. This role sees her promoting UK lifesciences and healthcare around the globe. ANGUS MCQUILKEN Vice President for Communications & Marketing at The Massachusetts Life Sciences Center Angus McQuilken joined the Massachusetts Life Sciences Center (MLSC) in 2008, and he currently serves as Vice President for Communications & Marketing. McQuilken serves as a member of the MLSC s senior management team, and he co-leads the Center s business development efforts that have drawn dozens of new companies to Massachusetts. Prior to his work at the MLSC, Angus served as Vice President for Public Affairs for Planned Parenthood League of Massachusetts, as Deputy Communications Director for the Democratic National Convention Committee, and as Chief of Staff for State Senator Cheryl Jacques. In 2008 he received the Distinguished Citizen Award from the Massachusetts chapter of the American Society for Public Administration. ANDRÉ SCHNEIDER Vice-President, EPFL (Ecole Polytechnique Fédérale de Lausanne) CEO and Chairman, André Schneider Global Advisory André Schneider expanded his experience joining the World Economic Forum and was instrumental during his 12 years in creating the world s leading global multi-stakeholder platform and finally globalizing this concept by expanding it around the world, with special emphasis on China and the Middle East. On August 1, 2013, André has joined EPFL, as Vice-President for Planning and Logistics. André is also the chairman of World Climate Ltd, the world s leading media and events platform to accelerate the development of the global green economy; Chairman of equal-salary, providing a certification of equal compensation for women and men; and Vice-Chairman of Global Infrastructure Basel, the sustainable infrastructure forum and summit. 5

6 ExportHelp s-ge.com/exporthelp T Stampfenbachstrasse 85 CH-8006 Zürich T Corso Elvezia 16 - CP 5399 CH-6901 Lugano T Avenue d Ouchy 47 - CP 315 CH-1001 Lausanne T s-ge.com STRATEGIC PARTNER COOPERATION PARTNER XL Group Insurance SWITZERLAND GLOBAL ENTERPRISE March All rights reserved.